Rapid Micro Biosystems to Present at 41st Annual J.P. Morgan Healthcare Conference

LOWELL, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference.

The Company is scheduled to present on Thursday, January 12, 2023 at 9:45am Pacific Time (12:45pm Eastern Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay for at least 30 days after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands.

For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.

CONTACT: Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
mbeaulieu@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

Staff

Recent Posts

DLA Piper Strengthens Market-leading Corporate Team With Addition of Partner Josh Seidenfeld in Silicon Valley

PALO ALTO--(BUSINESS WIRE)--DLA Piper has welcomed Josh Seidenfeld as Chair of the firm’s Northern California…

33 minutes ago

DLA Piper Strengthens Market-leading Corporate Team With Addition of Partner Josh Seidenfeld in Silicon Valley

PALO ALTO--(BUSINESS WIRE)--DLA Piper has welcomed Josh Seidenfeld as Chair of the firm’s Northern California…

33 minutes ago

Dandy Redefines the Chairside Experience with the Launch of Dandy Cart All-in-one workstation

Available at no additional cost, Dandy Cart turns scans into clear, visual stories, driving stronger…

37 minutes ago

Adia Nutrition Inc. Announces Dr. Brian Browning as Lead Physician for All Orthopedic Treatments and Specialties at Adia Med

Winter Park, Florida--(Newsfile Corp. - February 2, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a…

37 minutes ago